Revolution Medicines announces collaboration with Iambic

Revolution Medicines (RVMD) announced a technology and research collaboration to pursue novel drug candidates using Iambic’s AI models. In this multi-year agreement, Iambic will use structures and molecular libraries provided by Revolution Medicines to train bespoke versions of NeuralPLexer, Iambic’s industry-leading model for protein-ligand structure prediction. Revolution Medicines will also have access to Iambic’s PropANE model, a pre-trained graph neural network deployed across dozens of drug properties for lead selection and optimization. Under the agreement, Iambic will receive up to $25M through a combination of upfront and expected near-term performance-based milestone payments as well as ongoing research and development reimbursements.